

You've Been Prescribed PAXLOVID™

You were prescribed a 5-day course of PAXLOVID™ for the treatment of COVID-19. A small number of people who have COVID-19 experience a return of signs/symptoms after initially feeling better.

A clinical research study is now enrolling qualified participants to learn if an additional 5-day course of PAXLOVID may provide benefit for people with COVID-19 symptom rebound. [To assist in determining if you qualify, it is important to track symptoms for 14 days following your last dose of PAXLOVID. Please use the URL/QR code on the back of this card to sign up for daily text messages about your symptoms.] If it appears you may be experiencing a rebound of COVID-19 symptoms, it is important you are seen in our office within 48 hours.

For contact information, please see the back of this card.

Contact the Study Team

Contact the study team as soon as possible if you believe you are experiencing a rebound or worsening of your COVID-19 symptoms. [If you want help tracking your symptoms, join our Virtual Waiting Room for daily text messages to see if you may prequalify. Scan the QR code or visit the link to register.] The study site will review all criteria to determine your study eligibility.

Eastside Research Associates

(425) 869-6828 | participants@eastsideresearch.com

[eastsideresearch.com](https://www.eastsideresearch.com)



Thank you for considering this important study.

[PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.]

C4671042_PresCribed PAXLOVid-CARD_Us eN_V1_23seP22